Nanomix Enters into Distribution Agreement for the eLab System and Future New Products with BIOASIA PTE LTD in Singapore

Wednesday, August 24, 2022

Nanomix Corporation, a leading developer of affordable and portable point-of-care diagnostics, has announced a distribution agreement with BIOASIA PTE LTD ("Bioasia"), a medical diagnostics distributor based in Singapore. Bioasia will be responsible for marketing and distributing the Nanōmix eLab® system, including the Nanōmix S1 Panel assay and future test products, in Singapore and Brunei.

Henry Lim, Managing Director of Bioasia, expressed his satisfaction with the partnership, stating, "We are pleased to introduce much-needed diagnostics to our hospitals and customers. Sepsis and critical infections pose challenges in Singapore, as they do globally. Our collaboration with Nanomix will provide a unique option for our customers and the healthcare system in Singapore."

Thomas Schlumpberger, CEO of Nanomix, highlighted the company's progress in executing its commercialization strategy and the increasing interest in their products, particularly in Asia. The partnership with Bioasia represents a significant growth opportunity for Nanomix, starting in Singapore.

John Hardesky, Chief Commercial Officer of Nanomix, acknowledged Singapore's efficient healthcare system and emphasized the impact of the Nanōmix eLab® analyzer in diagnosing critical infections, including sepsis, within 12 minutes. This breakthrough in earlier sepsis patient diagnosis has the potential to bring significant advancements to healthcare.

Sepsis is a global health crisis that poses challenges for healthcare professionals worldwide. Early identification and treatment are crucial but often difficult. It is estimated that sepsis affects up to 50 million people annually and leads to approximately 11 million deaths each year.

The Nanōmix eLab® system is a portable and handheld immunoassay and chemistry diagnostic system designed for rapid point-of-care testing. It offers numerous advantages, including quick results, lower costs, and portability, while delivering accurate and quantitative results comparable to central lab testing. The S1 Panel Cartridge, developed to aid in the rapid diagnosis of critical infections, including sepsis, provides quantitative test results for procalcitonin (PCT), C-reactive protein (CRP), and lactate (LAC) from a single venous whole blood or plasma sample. The assay can be performed on the eLab® Analyzer, with results available in approximately 12 minutes, compared to hours required by current diagnostic solutions. The S1 Panel assay has received CE marking in Europe and is registered with the UK Medicines and Healthcare products Regulatory Agency (MHRA).

Harvard Medical School - Leadership in Medicine Southeast Asia47th IHF World Hospital CongressHealthcare CNO Summit - USAHealthcare CMO Summit - USA